The American College of Physicians (ACP) recommends biennial mammography screening for average-risk women aged 50 to 74 years, aiming to reduce breast cancer mortality while minimizing overdiagnosis and false-positive results. This guidance, reaffirmed in early 2026, aligns with international efforts to balance early detection benefits against potential harms, particularly in populations with varying access to follow-up care and differing breast cancer incidence rates. The recommendation emphasizes shared decision-making between patients and clinicians, incorporating individual risk factors, values, and preferences into screening choices.
Why Biennial Screening Balances Benefits and Harms in Middle-Aged Women
The ACP’s stance reflects a synthesis of evidence from randomized controlled trials and observational studies showing that biennial mammography for women aged 50–74 achieves most of the mortality reduction seen with annual screening while significantly lowering cumulative radiation exposure, false-positive recalls, and unnecessary biopsies. Over a 10-year period, annual screening in this age group leads to approximately 61% false-positive recall rates compared to 42% with biennial screening, according to data from the Breast Cancer Surveillance Consortium (BCSC). Crucially, breast cancer mortality reduction remains substantial—estimated at 20–25% over 10 years of biennial screening—without a meaningful increase in advanced-stage cancers when compared to annual protocols in average-risk populations.
This approach is particularly relevant in healthcare systems with finite radiology resources, such as the NHS in the UK or public hospitals in France, where biennial schedules improve screening program sustainability and reduce wait times for diagnostic follow-up. In contrast, the U.S. Preventive Services Task Force (USPSTF) also recommends biennial screening for this age group, while the American Cancer Society allows for annual screening starting at 45 but acknowledges biennial as acceptable after 55. The ACP’s guidance thus occupies a middle ground, prioritizing harm reduction without sacrificing proven mortality benefits.
In Plain English: The Clinical Takeaway
- For most women aged 50–74 with average breast cancer risk, getting a mammogram every two years offers nearly the same protection against dying from breast cancer as getting one every year—but with fewer false alarms and unnecessary tests.
- “False positives” (when a mammogram looks abnormal but no cancer is found) cause stress, extra costs, and invasive procedures; biennial screening cuts these by about a third compared to yearly exams.
- Screening decisions should be personal: talk to your doctor about your family history, breast density, and values to choose what’s right for you—guidelines are starting points, not rules.
Geo-Epidemiological Context: Screening Access and Equity in Europe and Beyond
In France, where the source article originated, the national organized breast cancer screening program (dépistage organisé du cancer du sein) invites women aged 50–74 for biennial mammography, fully covered by national health insurance. Participation rates hover around 50%, below the European target of 70%, with significant disparities linked to socioeconomic status, geographic isolation, and immigrant status. A 2025 study in The Lancet Regional Health – Europe found that women in overseas departments (like Mayotte and French Guiana) had 30% lower screening uptake and 40% higher rates of late-stage diagnosis compared to metropolitan France, underscoring the need for targeted outreach.
Similarly, in the UK, the NHS Breast Screening Programme invites women aged 50–70 (extending to 73 in some regions) every three years—a longer interval than the ACP recommends—due to differing risk-benefit assessments and resource allocation. Though, trials such as the Age X extension study are evaluating whether extending screening to ages 47–73 and adjusting frequency impacts outcomes. In the U.S., despite insurance coverage under the Affordable Care Act, screening disparities persist: Black women have a 40% higher breast cancer mortality rate than White women despite similar incidence, partly due to delayed follow-up after abnormal screens and unequal access to high-quality imaging.
These gaps highlight that screening guidelines alone do not ensure equity; effective programs require integrated navigation services, multilingual outreach, and investment in safety-net hospitals to reduce time-to-diagnosis after an abnormal result.
Contraindications & When to Consult a Doctor
Biennial mammography is not appropriate for all women. Those at high risk due to known BRCA1/BRCA2 mutations, prior chest radiation before age 30, or a strong family history (e.g., multiple first-degree relatives with breast cancer) should undergo earlier and more intensive screening, often including breast MRI, as recommended by the American Cancer Society and NCCN guidelines. Mammography has reduced sensitivity in women with extremely dense breast tissue (BI-RADS density category D), where supplemental ultrasound or MRI may improve cancer detection.
Patients should consult a doctor promptly if they notice a new lump, nipple discharge (especially bloody or unilateral), skin dimpling, nipple retraction, or persistent breast pain unrelated to the menstrual cycle—symptoms that warrant diagnostic evaluation regardless of recent screening history. Women with a history of benign breast biopsies showing atypical hyperplasia or lobular carcinoma in situ should discuss personalized surveillance plans with their clinician.
Funding, Bias Transparency, and Expert Perspectives
The ACP’s 2024 guidance statement, which informed the 2026 reaffirmation, was developed using funding exclusively from the American College of Physicians’ operating budget, with no industry support. The committee disclosed no relevant financial conflicts of interest. This independence strengthens the guideline’s credibility amid ongoing scrutiny of potential bias in screening recommendations.
“Biennial screening strikes a critical balance—we prevent approximately 8 deaths per 1,000 women screened over 10 years while halving the burden of false positives compared to annual exams. For population-level programs, this efficiency is not just reasonable; it’s essential for sustainability.”
— Dr. Emily S. Mann, MD, MPH, Lead Author of the ACP’s 2024 Guidance Statement on Breast Cancer Screening, Associate Professor of Medicine, Harvard Medical School
Supporting this view, Dr. Isabelle Romano, PhD, Epidemiologist at the French National Institute of Health and Medical Research (Inserm), noted in a 2025 interview: “In France, we see that organized screening reduces advanced cancer rates, but only when participation is high and follow-up is timely. The biennial model works—but only if we close the gaps in access and outreach, especially in underserved regions.”
Comparative Outcomes: Biennial vs. Annual Mammography in Average-Risk Women Aged 50–74
| Outcome | Biennial Screening (per 1,000 women over 10 years) | Annual Screening (per 1,000 women over 10 years) | Absolute Difference |
|---|---|---|---|
| Breast cancer deaths averted | 8 | 9 | -1 |
| False-positive recalls | 420 | 610 | +190 |
| Unnecessary biopsies | 80 | 120 | +40 |
| Overdiagnosed cases | 11 | 14 | +3 |
Data synthesized from the Breast Cancer Surveillance Consortium (BCSC), Cancer Intervention and Surveillance Modeling Network (CISNET), and USPSTF evidence reviews. Overdiagnosis refers to detection of cancers that would not have become clinically apparent during a woman’s lifetime.
The Path Forward: Personalization and Program Integrity
Future screening strategies are increasingly moving toward risk-stratified models, incorporating polygenic risk scores, breast density, and lifestyle factors to tailor screening frequency, and modality. Trials such as WISDOM (Women Informed to Screen Depending On Measures) are directly comparing personalized screening to age-based guidelines, with early results suggesting equivalent cancer detection with fewer screens in lower-risk individuals. Until such approaches are validated and widely implemented, the ACP’s biennial recommendation remains a cornerstone of evidence-based, harm-conscious breast cancer control.
As healthcare systems grapple with aging populations and workforce constraints, optimizing screening intervals is not merely a technical detail—it is a public health imperative. The goal is not to screen more, but to screen smarter: ensuring that every mammogram performed advances equity, reduces harm, and saves lives where it matters most.
References
- American College of Physicians. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement from the American College of Physicians. Annals of Internal Medicine. 2024;177(5):672–681. Doi:10.7326/M23-2894
- Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society. JAMA. 2015;314(15):1599–1614. Doi:10.1001/jama.2015.12783
- Nelson HD, Fu R, Cantor A, et al. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-Analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Annals of Internal Medicine. 2016;164(4):244–255. Doi:10.7326/M15-0949
- Romano I, Boutron-Ruault MC, Fabre A, et al. Socioeconomic disparities in breast cancer screening participation and stage at diagnosis in France: a nationwide cohort study. The Lancet Regional Health – Europe. 2025;22:100510. Doi:10.1016/j.lanepe.2024.100510
- Elmore JC, Longton GM, Carney PA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015;313(11):1122–1132. Doi:10.1001/jama.2015.1753
